Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai To Launch Digestive Drug In Thailand, Add Staff

This article was originally published in PharmAsia News

Executive Summary

Eisai plans to increase its sales staff in Thailand as it steps up marketing of its Gasmotin (mosapride) digestive-track drug in Southeast Asia where it has marketing rights. Eisai currently has 10 sales people stationed in Thailand, but expects to begin expanding the staff to 80 to sell the drug expected to be launched by the end of the year. Eisai markets the drug for Dainippon Sumitomo Pharma, its developer. Eisai has applied for approval in Indonesia, Malaysia and The Philippines, and is set to apply in Cambodia, Laos, Myanmar, Singapore, Sri Lanka and Vietnam.(Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts